A major trial has provided more details about the risk of lung injury with low dose methotrexate (MTX) and in particular for MTX-related pneumonitis. One of the largest studies ever of low dose methotrexate use – involving 2,391 people randomised to receive the drug – showed a rate of severe pulmonary adverse events of 0.5%, ...
New details emerge on pulmonary adverse effects of low-dose MTX
By Michael Woodhead
13 Oct 2020